CD274 and non-small cell lung carcinoma: The phase III MYSTIC and CHECKMATE-026 studies of durvalumab and nivolumab, respectively, versus platinum chemotherapy in patients with PD-L1 positive (tumor cell 1% or more) NSCLC both failed to meet their primary endpoints of improved overall survival [56,58].